Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference By Investing.com

– The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April

– Samsung (KS:) Biologics to offer ADC services and invest in advanced development and manufacturing capabilities to better address clients’ needs

INCHEON, South Korea, Jan. 14, 2025 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan Healthcare Conference, which was held in San Francisco between January 13-16.

During the main track presentation, Samsung Biologics’ CEO and President John Rim said, “Despite industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in 2025 with the opening of Bio Campus II and launch of antibody-drug conjugate (ADC) services.” He added, “We’ll continue to invest in new modalities and technologies to better address client needs, maximizing satisfaction and ensuring the delivery of highest-quality products.”

Key business updates include:

ADC services: To address the increasing demand for ADC-based therapeutics, Samsung Biologics has commenced ADC services at its new dedicated facility. Building on the company’s expertise in large-scale antibody manufacturing and process engineering, Samsung Biologics’ service scope spans late stage discovery, development, and conjugation. Samsung Biologics recently expanded its  collaboration with LigaChem Biosciences to support a series of their ADC programs at Samsung Biologics’ new dedicated ADC facility.

Opening of Japan office: To better support Samsung Biologics’ expanding global client base, the company announced plans to open a regional office in Tokyo this year. The local presence will boost Samsung Biologics ability to support and grow its increasing partnerships in Japan.

Expanded Drug Product (DP) services: As part of continued efforts to expand service offerings, Samsung Biologics is investing in pre-filled syringe (PFS) capabilities. The company’s fully automated PFS DP line will be CGMP ready by 2027.  

Enhanced development capabilities: Samsung Biologics plans to better support global pharma and emerging biotech companies by investing in core development capabilities. The company is offering services incorporating new tech platforms, including S-HiCon^™, S-Tensify^™, S-AfuCHO^™, and S-OptiCharge^™, that ensure higher productivity and quality of a molecule for successful and…